{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:30:49Z","timestamp":1787009449273,"version":"build-2736575974"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2019,12,31]],"date-time":"2019-12-31T00:00:00Z","timestamp":1577750400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1U54HD090259"],"award-info":[{"award-number":["1U54HD090259"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1U01AI124316"],"award-info":[{"award-number":["1U01AI124316"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI132627"],"award-info":[{"award-number":["R01AI132627"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI121400"],"award-info":[{"award-number":["R01AI121400"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Daptomycin and ceftaroline (DAP-CPT) have been used for persistent methicillin-resistant Staphylococcus aureus bacteremia (MRSAB), but have rarely been compared with other therapies. This study provides an exploratory analysis of patients placed on DAP-CPT vs standard of care (SOC) for MRSAB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a retrospective, matched cohort study MRSAB patients at 4 hospitals in the United States. Patients receiving DAP-CPT for \u226572 hours at any point in therapy were matched 2:1 when possible, 1:1 otherwise, to SOC, first by infection source, then age and renal function. SOC was empiric treatment with vancomycin or daptomycin and any subsequent combination antibiotic(s), except for DAP-CPT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Fifty-eight patients received DAP-CPT with 113 matched SOC. Ninety-six percent of SOC received vancomycin, and 56% (63\/113) escalated therapy at least once in the treatment course. Twenty-four patients received DAP-CPT within 72 hours of index culture; 2 (8.3%) died within 30 days vs 14.2% (16\/113) with SOC (P\u2005&amp;gt;\u2005.05). Subgroup analysis identified numerically lower mortality in DAP-CPT patients with a Charlson comorbidity index \u22653, endovascular source, and receipt of DAP-CPT within 72 hours of index culture. The median MRSAB duration was 9.3 vs 4.8 days for DAP-CPT and SOC, respectively. DAP-CPT was initiated on day 6 on average; after receipt of DAP-CPT, MRSAB duration was 3.3 days.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>DAP-CPT treatment is often delayed in MRSAB. Combination therapy may be more beneficial if initiated earlier, particularly in patients at higher risk for mortality. Blinded, randomized, prospective studies are needed to eliminate selection bias inherent in retrospective analyses when examining DAP-CPT vs SOC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofz538","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T21:48:19Z","timestamp":1577742499000},"source":"Crossref","is-referenced-by-count":88,"title":["Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments"],"prefix":"10.1093","volume":"7","author":[{"given":"Erin K","family":"McCreary","sequence":"first","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin Health, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ravina","family":"Kullar","sequence":"additional","affiliation":[{"name":"Expert Stewardship, Newport Beach, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Geriak","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Sharp Memorial Hospital, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan J","family":"Zasowski","sequence":"additional","affiliation":[{"name":"Infectious Disease, Sharp Healthcare, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khulood","family":"Rizvi","sequence":"additional","affiliation":[{"name":"Wayne State University School of Medicine, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas T","family":"Schulz","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin Health, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista","family":"Ouellette","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Sharp Memorial Hospital, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Logan","family":"Vasina","sequence":"additional","affiliation":[{"name":"Pharmacy Department, Sharp Memorial Hospital, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Haddad","sequence":"additional","affiliation":[{"name":"Infectious Disease, Sharp Healthcare, San Diego, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J","family":"Rybak","sequence":"additional","affiliation":[{"name":"Anti-Infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA"},{"name":"Wayne State University School of Medicine, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus J","family":"Zervos","sequence":"additional","affiliation":[{"name":"Wayne State University School of Medicine, Detroit, Michigan, USA"},{"name":"Division of Infectious Diseases, Henry Ford Health System, Detroit, Michigan, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Sakoulas","sequence":"additional","affiliation":[{"name":"Infectious Disease, Sharp Healthcare, San Diego, California, USA"},{"name":"Division of Host-Microbe Systems & Therapeutics, Center for Immunity, Infection & Inflammation, University of California-San Diego School of Medicine, La Jolla, California, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5012-5993","authenticated-orcid":false,"given":"Warren E","family":"Rose","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, University of Wisconsin Health, Madison, Wisconsin, USA"},{"name":"School of Pharmacy, University of Wisconsin-Madison, Madison, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,12,31]]},"reference":[{"key":"2020010910575991100_CIT0001","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020010910575991100_CIT0002","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1093\/jac\/dkv368","article-title":"When sepsis persists: a review of MRSA bacteraemia salvage therapy","volume":"71","author":"Kullar","year":"2016","journal-title":"J Antimicrob Chemother"},{"key":"2020010910575991100_CIT0003","doi-asserted-by":"crossref","first-page":"6192","DOI":"10.1128\/AAC.01525-12","article-title":"\u03b2-lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives","volume":"56","author":"Mehta","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020010910575991100_CIT0004","doi-asserted-by":"crossref","first-page":"5046","DOI":"10.1128\/AAC.00502-12","article-title":"Altering the proclivity towards daptomycin resistance in methicillin-resistant Staphylococcus aureus using combinations with other antibiotics","volume":"56","author":"Berti","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020010910575991100_CIT0005","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1093\/jac\/dku322","article-title":"Vancomycin plus ceftaroline shows potent in vitro synergy and was successfully utilized to clear persistent daptomycin-non-susceptible MRSA bacteraemia","volume":"70","author":"Barber","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020010910575991100_CIT0006","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/jac\/dku378","article-title":"The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA","volume":"70","author":"Barber","year":"2015","journal-title":"J Antimicrob Chemother"},{"key":"2020010910575991100_CIT0007","doi-asserted-by":"crossref","first-page":"4497","DOI":"10.1128\/AAC.00386-15","article-title":"Evaluation of ceftaroline alone and in combination against biofilm-producing methicillin-resistant Staphylococcus aureus with reduced susceptibility to daptomycin and vancomycin in an in vitro pharmacokinetic\/pharmacodynamic model","volume":"59","author":"Barber","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"2020010910575991100_CIT0008","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1002\/phar.2034","article-title":"Early administration of adjuvant \u03b2-lactam therapy in combination with vancomycin among patients with methicillin-resistant Staphylococcus aureus bloodstream infection: a retrospective, multicenter analysis","volume":"37","author":"Casapao","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"2","key":"2020010910575991100_CIT0009","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1093\/cid\/civ808","article-title":"Combination of vancomycin and beta-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial","volume":"62","author":"Davis","year":"2016","journal-title":"Clin Infect Dis"},{"key":"2020010910575991100_CIT0010","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.clinthera.2014.05.061","article-title":"Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline","volume":"36","author":"Sakoulas","year":"2014","journal-title":"Clin Ther"},{"key":"2020010910575991100_CIT0011","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.1128\/AAC.02371-13","article-title":"Large retrospective evaluation of the effectiveness and safety of ceftaroline fosamil therapy","volume":"58","author":"Casapao","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020010910575991100_CIT0012","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s10156-012-0449-9","article-title":"The use of ceftaroline fosamil in methicillin-resistant Staphylococcus aureus endocarditis and deep-seated MRSA infections: a retrospective case series of 10 patients","volume":"19","author":"Lin","year":"2013","journal-title":"J Infect Chemother"},{"key":"2020010910575991100_CIT0013","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.ijantimicag.2019.01.014","article-title":"Ceftaroline fosamil for the treatment of Gram-positive endocarditis: CAPTURE study experience","volume":"53","author":"Destache","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"2020010910575991100_CIT0014","doi-asserted-by":"crossref","first-page":"5296","DOI":"10.1128\/AAC.00797-12","article-title":"Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity","volume":"56","author":"Rose","year":"2012","journal-title":"Antimicrob Agents Chemother"},{"key":"2020010910575991100_CIT0015","doi-asserted-by":"crossref","first-page":"e02015","DOI":"10.1128\/AAC.02015-16","article-title":"Multicenter observational study of ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"61","author":"Zasowski","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"2020010910575991100_CIT0016","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.drup.2013.10.002","article-title":"Reduced glycopeptide and lipopeptide susceptibility in Staphylococcus aureus and the \u201cseesaw effect\u201d: taking advantage of the back door left open?","volume":"16","author":"Ortwine","year":"2013","journal-title":"Drug Resist Updat"},{"key":"2020010910575991100_CIT0017","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s40121-014-0023-0","article-title":"Observation of \u201cseesaw effect\u201d with vancomycin, teicoplanin, daptomycin and ceftaroline in 150 unique MRSA strains","volume":"3","author":"Barber","year":"2014","journal-title":"Infect Dis Ther"},{"key":"2020010910575991100_CIT0018","doi-asserted-by":"crossref","first-page":"2664","DOI":"10.1128\/AAC.02308-12","article-title":"Evaluation of ceftaroline activity against heteroresistant vancomycin-intermediate Staphylococcus aureus and vancomycin-intermediate methicillin-resistant S. aureus strains in an in vitro pharmacokinetic\/pharmacodynamic model: exploring the \u201cseesaw effect\u201d","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020010910575991100_CIT0019","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.clinthera.2014.09.005","article-title":"Daptomycin in combination with other antibiotics for the treatment of complicated methicillin-resistant Staphylococcus aureus bacteremia","volume":"36","author":"Dhand","year":"2014","journal-title":"Clin Ther"},{"key":"2020010910575991100_CIT0020","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1128\/AAC.01586-12","article-title":"Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic\/pharmacodynamic model","volume":"57","author":"Werth","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2020010910575991100_CIT0021","doi-asserted-by":"crossref","first-page":"e02483","DOI":"10.1128\/AAC.02483-18","article-title":"Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"63","author":"Geriak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2020010910575991100_CIT0022","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1093\/cid\/cix157","article-title":"Increased endovascular Staphylococcus aureus inoculum is the link between elevated serum interleukin 10 concentrations and mortality in patients with bacteremia","volume":"64","author":"Rose","year":"2017","journal-title":"Clin Infect Dis"},{"key":"2020010910575991100_CIT0023","doi-asserted-by":"crossref","first-page":"1604","DOI":"10.1093\/infdis\/jis552","article-title":"Elevated serum interleukin-10 at time of hospital admission is predictive of mortality in patients with Staphylococcus aureus bacteremia","volume":"206","author":"Rose","year":"2012","journal-title":"J Infect Dis"},{"key":"2020010910575991100_CIT0024","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J Chronic Dis"},{"key":"2020010910575991100_CIT0025","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1128\/AAC.36.12.2639","article-title":"Prospective observational study of Klebsiella bacteremia in 230 patients: outcome for antibiotic combinations versus monotherapy","volume":"36","author":"Korvick","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"2020010910575991100_CIT0026","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1444-0903.2001.00029.x","article-title":"Prospective study of 424 cases of Staphylococcus aureus bacteraemia: determination of factors affecting incidence and mortality","volume":"31","author":"Hill","year":"2001","journal-title":"Intern Med J"},{"key":"2020010910575991100_CIT0027","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1159\/000180580","article-title":"Prediction of creatinine clearance from serum creatinine","volume":"16","author":"Cockcroft","year":"1976","journal-title":"Nephron"},{"key":"2020010910575991100_CIT0028","article-title":"Daptomycin plus beta-lactam combination therapy for methicillin-resistant Staphylococcus aureus bloodstream infections: a retrospective, comparative cohort study","author":"Jorgensen","year":"","journal-title":"Clin Infect"},{"key":"2020010910575991100_CIT0029","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir034","article-title":"Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children: executive summary","volume":"52","author":"Liu","year":"2011","journal-title":"Clin Infect Dis"},{"key":"2020010910575991100_CIT0030","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/CMR.05022-11","article-title":"Predictors of mortality in Staphylococcus aureus bacteremia","volume":"25","author":"van Hal","year":"2012","journal-title":"Clin Microbiol Rev"},{"key":"2020010910575991100_CIT0031","doi-asserted-by":"crossref","first-page":"e0170236","DOI":"10.1371\/journal.pone.0170236","article-title":"Characteristics of Staphylococcus aureus bacteraemia and predictors of early and late mortality","volume":"12","author":"Bassetti","year":"2017","journal-title":"PLoS One"},{"key":"2020010910575991100_CIT0032","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ijid.2017.05.010","article-title":"Risk factors for 30-day mortality in patients with methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"61","author":"Ayau","year":"2017","journal-title":"Int J Infect Dis"},{"key":"2020010910575991100_CIT0033","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1007\/s10096-012-1585-y","article-title":"Formal infectious diseases consultation is associated with decreased mortality in Staphylococcus aureus bacteraemia","volume":"31","author":"Robinson","year":"2012","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"2020010910575991100_CIT0034","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jinf.2014.05.004","article-title":"Mandatory infectious diseases consultation for MRSA bacteremia is associated with reduced mortality","volume":"69","author":"Tissot","year":"2014","journal-title":"J Infect"},{"key":"2020010910575991100_CIT0035","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1128\/AAC.01204-13","article-title":"\u03b2-lactams enhance vancomycin activity against methicillin-resistant Staphylococcus aureus bacteremia compared to vancomycin alone","volume":"58","author":"Dilworth","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2020010910575991100_CIT0036","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2146\/ajhp080434","article-title":"Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists","volume":"66","author":"Rybak","year":"2009","journal-title":"Am J Health Syst Pharm"},{"key":"2020010910575991100_CIT0037","first-page":"L0014","article-title":"Combination antibiotic therapy for methicillin-resistant Staphylococcus aureus bacteraemia: the CAMERA2 randomised controlled trial","volume-title":"European Congress on Clinical Microbiology and Infectious Diseases;","author":"Davis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofz538\/31660379\/ofz538.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/1\/ofz538\/31778730\/ofz538.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ofid\/article-pdf\/7\/1\/ofz538\/31778730\/ofz538.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,14]],"date-time":"2021-02-14T09:43:29Z","timestamp":1613295809000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofz538\/5691187"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,31]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofz538","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.737218001.793587623","asserted-by":"object"}]},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2019,12,31]]},"article-number":"ofz538"}}